Pheochromocytoma

Overview

• Definition: Pheochromocytoma is a rare, catecholamine-secreting neuroendocrine tumor that arises from chromaffin cells, most commonly found in the adrenal medulla. When these tumors arise from extra-adrenal chromaffin tissue, they are termed paragangliomas. These tumors produce, store, and secrete excessive amounts of catecholamines (norepinephrine, epinephrine, and/or dopamine), leading to a variety of symptoms, most notably hypertension.
• Epidemiology: Pheochromocytomas are rare, with an estimated incidence of 0.8 per 100,000 person-years. They are found in approximately 0.1-0.6% of all hypertensive patients. The classic "Rule of 10s" (10% extra-adrenal, 10% malignant, 10% bilateral, 10% familial, 10% pediatric, 10% asymptomatic) is an oversimplification and increasingly inaccurate due to advancements in genetic testing and imaging. For example, familial cases now account for >50% of pheochromocytomas. The peak incidence is between the third and fifth decades of life, but they can occur at any age.
• Classification:
  • Location:
    • Adrenal Pheochromocytoma: Originates in the adrenal medulla (approximately 80-85% of cases).
    • Extra-adrenal Paraganglioma (PGL): Arises from sympathetic or parasympathetic paraganglia outside the adrenal glands (approximately 15-20% of cases). Sympathetic PGLs are typically found in the abdomen/pelvis and are usually catecholamine-secreting. Parasympathetic PGLs are usually found in the head and neck, are often non-secretory, and are often associated with SDHx mutations.
  • Functionality:
    • Functional (Secretory): Secrete excessive catecholamines and their metabolites, leading to symptoms.
    • Non-functional (Non-secretory): Produce little to no active catecholamines, often presenting as an incidental mass.
  • Benign vs. Malignant: Traditionally, malignancy is defined by the presence of metastases, as there are no definitive histological features to distinguish benign from malignant tumors. Approximately 10-17% of pheochromocytomas are malignant.
  • Sporadic vs. Hereditary: Approximately 50-70% of pheochromocytomas/paragangliomas are sporadic, while the remainder are hereditary, associated with germline mutations in various susceptibility genes (e.g., RET, VHL, NF1, SDHB, SDHD, TMEM127, MAX, FH).

Pathophysiology

• Mechanism: Pheochromocytomas and paragangliomas are tumors of chromaffin cells that synthesize, store, and release supraphysiologic amounts of catecholamines, primarily norepinephrine and epinephrine, and to a lesser extent, dopamine. The specific catecholamine profile depends on the tumor's location and genetic background.
  • Norepinephrine (NE): Predominant catecholamine produced by most extra-adrenal paragangliomas and some adrenal pheochromocytomas. Primarily causes vasoconstriction and hypertension.
  • Epinephrine (E): Primarily produced by adrenal pheochromocytomas, as the adrenal medulla contains phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts NE to E. Causes cardiac stimulation (tachycardia, palpitations), metabolic effects (hyperglycemia), and vasodilation in some vascular beds.
  • Dopamine (DA): Elevated in some tumors, particularly those with SDHB mutations. Its role in symptoms is less clear, but it can contribute to hypertension.
• Risk Factors:
  • Genetic Syndromes: This is the most significant risk factor. Patients with the following germline mutations have an increased risk:
    • Multiple Endocrine Neoplasia type 2 (MEN2A and MEN2B): Associated with RET proto-oncogene mutations (typically secrete epinephrine).
    • Von Hippel-Lindau (VHL) disease: Associated with VHL gene mutations (typically secrete norepinephrine).
    • Neurofibromatosis type 1 (NF1): Associated with NF1 gene mutations.
    • Succinate Dehydrogenase (SDH) gene mutations (SDHA, SDHB, SDHC, SDHD, SDHAF2): Particularly SDHB mutations are associated with a higher risk of malignant and extra-adrenal paragangliomas, often secreting norepinephrine/dopamine.
    • Other rare mutations: TMEM127, MAX, FH, etc.
  • Family History: A family history of pheochromocytoma, paraganglioma, or related genetic syndromes.
  • Prior History: Previous diagnosis of pheochromocytoma or paraganglioma.
  • Incidental Adrenal Mass: A non-functional adrenal incidentaloma has a small but definite risk of being a pheochromocytoma.
• Protective Factors: No known protective factors against the development of pheochromocytoma. Early diagnosis and treatment are crucial to prevent severe complications and improve prognosis.

Clinical Presentation

Signs and Symptoms

Clinical presentation is highly variable, ranging from asymptomatic to life-threatening hypertensive crises. Symptoms are often paroxysmal, lasting minutes to hours, but can be sustained. - Cardinal Features (Classic Triad): These three symptoms occur together in approximately 30-50% of symptomatic patients: 1. Headaches: Severe, throbbing, often frontal, sudden onset. 2. Sweating: Profuse, generalized diaphoresis. 3. Palpitations: Tachycardia, awareness of heart beat, often described as pounding. - Other Common Symptoms: - Hypertension: Can be sustained (50-60%), paroxysmal (30-40%), or a combination. Often severe and resistant to conventional antihypertensive therapy. Hypertensive crises can be triggered by stress, exercise, certain medications (e.g., tricyclic antidepressants, opioids, decongestants), or tumor manipulation. - Anxiety/Panic Attacks: Often profound, with a sense of impending doom. - Tremor: Fine tremor, often with anxiety. - Pallor: Due to generalized vasoconstriction. - Chest Pain: Angina-like pain, myocardial ischemia. - Abdominal Pain: Often vague, can be associated with tumor mass effect or ischemia. - Nausea and Vomiting: - Weight Loss: Despite normal or increased appetite. - Glucose Intolerance/Diabetes Mellitus: Catecholamine-induced insulin resistance and inhibition of insulin secretion. - Orthostatic Hypotension: Due to chronic vasoconstriction leading to intravascular volume depletion, paradoxical effect when standing. - Early Signs: May be subtle, such as episodic anxiety, mild hypertension, or unexplained palpitations/sweating, often dismissed as stress or anxiety disorders. - Advanced Signs: Manifestations of end-organ damage from chronic or severe catecholamine excess: - Hypertensive retinopathy (papilledema, hemorrhages, exudates). - Cardiomyopathy (dilated or hypertrophic, catecholamine-induced myocarditis). - Myocardial infarction, stroke, dissecting aortic aneurysm. - Acute renal failure. - Pulmonary edema. - Multi-organ failure, sudden death. - Atypical Presentations: - Asymptomatic: Found incidentally during imaging for other reasons (adrenal incidentaloma). - Normotensive Pheochromocytoma: Rare, but can occur, especially if the tumor primarily secretes dopamine or if it has undergone necrosis. - Hypotension/Shock: Can occur due to tumor necrosis, hemorrhage, or excessive sympathetic outflow followed by profound vasodilation. - Fever of Unknown Origin: Rare. - Bradycardia: Very rare, usually due to paradoxical vagal stimulation. - Bowel obstruction: Due to tumor mass effect.

Physical Examination

Findings can vary from normal between episodes to overt signs of catecholamine excess during a crisis. - Inspection: - General: Anxious appearance, diaphoresis, pallor. - Cutaneous: Cafe-au-lait spots, neurofibromas, axillary freckling (suggestive of NF1). - Constitutional: Marfanoid habitus, mucosal neuromas (suggestive of MEN2B). - Thyroid: Palpable thyroid nodule/goiter (suggestive of MEN2A/B, medullary thyroid cancer). - Palpation: - Abdomen: Rarely, a palpable abdominal mass (usually large tumors). - Neck: Palpable cervical paragangliomas (carotid body tumors). - Thyroid: Palpable thyroid nodules (MEN2). - Auscultation: - Cardiovascular: Tachycardia, irregular rhythm (arrhythmias), heart murmurs (cardiomyopathy). - Abdominal: Bruits may indicate renal artery stenosis, which can coexist. - Special Tests: - Blood Pressure: Careful measurement of blood pressure, both supine and standing, to detect sustained or paroxysmal hypertension, and orthostatic hypotension. Orthostatic hypotension (drop in SBP ≥20 mmHg or DBP ≥10 mmHg) is a common finding due to chronic vasoconstriction and volume depletion. - Funduscopic Exam: To assess for hypertensive retinopathy (arteriolar narrowing, hemorrhages, exudates, papilledema).

Diagnostic Approach

History Taking

• Key Questions:
  • Symptom Characterization: Detailed description of paroxysmal symptoms (headaches, palpitations, sweating, anxiety, chest pain, abdominal pain). Frequency, duration, severity, and triggers (e.g., exercise, stress, specific foods/drinks, medications).
  • Hypertension History: Onset, pattern (sustained, paroxysmal), severity, and response to antihypertensive medications (especially if resistant).
  • Family History: Any family members with pheochromocytoma, paraganglioma, early-onset hypertension, medullary thyroid carcinoma, parathyroid adenoma, VHL disease, NF1, or other genetic syndromes.
  • Medication Review: Use of medications that can trigger or exacerbate symptoms (e.g., tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), cold remedies containing pseudoephedrine/phenylephrine, metoclopramide, opioids).
  • Past Medical History: Previous adrenal incidentaloma, genetic screening results.
  • General Health: Unexplained weight loss, glucose intolerance.
• Red Flags:
  • Recurrent, severe, episodic headaches, palpitations, and sweating, especially if associated with hypertensive surges.
  • Resistant hypertension (uncontrolled despite ≥3 antihypertensive agents of different classes, one of which is a diuretic).
  • Paroxysmal hypertension, particularly with orthostatic hypotension.
  • Family history suggestive of a genetic pheochromocytoma syndrome.
  • Adrenal incidentaloma, especially if >3 cm or with suspicious imaging characteristics (high Hounsfield units, delayed washout).
  • Pressor response during general anesthesia or surgery.

Laboratory Tests

Biochemical confirmation of catecholamine excess is the cornerstone of diagnosis. - First-Line: - Plasma Free Metanephrines: Highly sensitive (97-100%) and specific (82-98%). Recommended by most guidelines. Patient should be supine for 20-30 minutes prior to blood draw. Certain drugs (e.g., tricyclic antidepressants, phenoxybenzamine, levodopa, some decongestants) and stressors can falsely elevate levels. - Values: Levels >2-3 times the upper limit of normal (ULN) are highly suggestive of pheochromocytoma. Levels slightly above ULN (e.g., 1-2x ULN) often require careful interpretation, exclusion of interfering factors, and potentially repeat testing or further investigation. - 24-hour Urine Fractionated Metanephrines and Catecholamines: Also highly sensitive (97-100%) and specific (88-99%). Less susceptible to acute stress-induced fluctuations. Requires careful patient instruction for collection. - Values: Similar to plasma, significant elevations >2-3x ULN are highly indicative. Mild elevations should be interpreted cautiously. - Considerations: Plasma free metanephrines are generally preferred for ease of collection and slightly higher diagnostic accuracy in many settings. Urine tests may be preferred in patients with renal impairment. - Confirmatory: - Genetic Testing: Recommended for all patients with confirmed pheochromocytoma/paraganglioma, given the high prevalence of germline mutations. Targeted gene panels are usually employed. Identifies predisposition, guides management, and aids in screening family members. - Clonidine Suppression Test: Rarely used now. For patients with borderline elevations of catecholamines/metanephrines, differentiates true pheochromocytoma from essential hypertension. Clonidine suppresses neurogenic catecholamine release but not tumor-derived release. (Not recommended by current guidelines as first-line for diagnosis due to excellent sensitivity/specificity of metanephrine assays). - Glucagon Stimulation Test: Also rarely used, potentially dangerous. Glucagon can precipitate a hypertensive crisis in patients with pheochromocytoma. Reserved for equivocal cases where suspicion remains high, and other tests are inconclusive. - Monitoring: - Post-operative: Biochemical re-evaluation (plasma or urine metanephrines/catecholamines) 2-6 weeks after surgery to confirm complete biochemical resection. - Long-term Surveillance: Annual biochemical testing for life (or as clinically indicated) to detect recurrence or new primary tumors, especially in patients with genetic syndromes.

Imaging

Imaging studies are performed after biochemical confirmation to localize the tumor. - Recommended: - Computed Tomography (CT) of the Abdomen/Pelvis: High spatial resolution, widely available. Performed with and without intravenous contrast. Adrenal pheochromocytomas typically appear as well-defined, heterogeneous masses, often >3 cm, with high attenuation on non-contrast CT (>10 Hounsfield units) and delayed washout of contrast. - Magnetic Resonance Imaging (MRI) of the Abdomen/Pelvis: Preferred in pregnant patients, children, or when radiation exposure is a concern. Pheochromocytomas often demonstrate high signal intensity on T2-weighted images ("light bulb" sign), but this is not pathognomonic. Contrast-enhanced MRI (gadolinium) is typically used. - Advanced (Functional Imaging): Used for localization when standard anatomical imaging is negative, for screening in genetic syndromes, or for detecting metastatic disease. - $^{123}$I-Metaiodobenzylguanidine (MIBG) Scintigraphy: MIBG is an analog of norepinephrine that is taken up by adrenergic tissues. Useful for identifying multifocal, metastatic, or extra-adrenal pheochromocytomas/paragangliomas. Sensitivity ~77-90%, specificity ~90-100%. Less sensitive for SDH-related tumors. - Positron Emission Tomography (PET) Scans: - $^{18}$F-Fluorodeoxyglucose (FDG)-PET: Useful for detecting metastatic or rapidly growing tumors, particularly in malignant or SDHB-related paragangliomas, which tend to be metabolically active. - $^{18}$F-Fluorodopamine (FDA)-PET: High sensitivity and specificity for both adrenal and extra-adrenal tumors. - $^{68}$Ga-DOTATATE PET/CT: Highly sensitive for detection of primary and metastatic pheochromocytomas/paragangliomas, particularly those expressing somatostatin receptors (common in head/neck paragangliomas and SDH-related tumors). Often superior to MIBG for detecting SDH-related tumors and metastatic disease.

Management

Acute Management

Acute management focuses on controlling the effects of excessive catecholamines, particularly hypertension and arrhythmias. - Immediate: - Hypertensive Crisis: IV vasodilators are the mainstay. - Phentolamine: Non-selective alpha-adrenergic blocker. Initial bolus 1-5 mg IV, then continuous infusion of 1-5 mg/hour. Rapid onset, short duration. - Nicardipine: Calcium channel blocker. Initial infusion 5 mg/hour, titrated up to 15 mg/hour. - Sodium Nitroprusside: Nitric oxide donor, potent vasodilator. Infusion 0.5-10 mcg/kg/min. Requires arterial line for continuous BP monitoring. Risk of cyanide toxicity with prolonged use. - Tachycardia/Arrhythmias: Beta-blockers can be used only after adequate alpha-adrenergic blockade to prevent unopposed alpha-stimulation leading to worsening hypertension. - Esmolol: Short-acting beta-blocker. Loading dose 0.5 mg/kg IV over 1 minute, then 50-200 mcg/kg/min infusion. - Propranolol: 0.5-3 mg IV slow push. - Stabilization: - Volume Expansion: Patients are often chronically volume-depleted due to persistent vasoconstriction. Administer intravenous normal saline (e.g., 1-2 liters over a few hours) to expand intravascular volume, especially prior to surgery. - Continuous Monitoring: Admit to an intensive care unit (ICU) for continuous cardiac and blood pressure monitoring. - Emergency: In severe cases such as acute heart failure, myocardial infarction, or stroke, management follows standard protocols for these conditions, with concurrent aggressive control of catecholamine effects.

Chronic Management

The definitive treatment for resectable pheochromocytoma is surgical removal, but meticulous pre-operative preparation is critical. - Pharmacological (Pre-operative): - Alpha-Adrenergic Blockade: Essential to prevent intraoperative hypertensive crises. Initiated 7-14 days before surgery. - Phenoxybenzamine: Non-selective, irreversible alpha-adrenergic blocker. Start 10 mg orally once or twice daily, titrate gradually by 10-20 mg every 2-3 days to achieve target blood pressure and symptom control. Typical maintenance dose is 20-100 mg/day in divided doses. Aim for sitting BP <130/80 mmHg and standing SBP >90 mmHg. - Selective Alpha-1 Blockers (e.g., Doxazosin, Terazosin, Prazosin): Shorter acting, reversible. Doxazosin typically started at 1-2 mg orally once daily, titrated upwards (up to 16 mg/day). May have fewer side effects (e.g., less reflex tachycardia) but require more frequent dosing and may be less effective in preventing intraoperative crises than phenoxybenzamine in some cases. - Beta-Adrenergic Blockade: Only initiated after adequate alpha-blockade has been established (typically 2-3 days after alpha-blocker initiation). Used to control tachycardia, arrhythmias, and palpitations. - Propranolol: 10-40 mg orally three to four times daily. - Metoprolol: 25-100 mg orally twice daily. - Calcium Channel Blockers: Can be added if blood pressure remains uncontrolled despite maximal alpha-blockade (e.g., Amlodipine 5-10 mg daily, Nicardipine). - Non-pharmacological: - High Sodium Diet and Fluid Intake: During alpha-blockade, encourage a high-sodium diet (e.g., 5 grams sodium/day) and adequate fluid intake (e.g., 2-3 liters/day) to expand intravascular volume and minimize orthostatic hypotension. - Monitoring: - Pre-operative: Daily monitoring of blood pressure (supine and standing), heart rate, and orthostatic symptoms. - Long-term: Post-operative biochemical surveillance (annual plasma or urine metanephrines/catecholamines) for life due to risk of recurrence or new primary tumors, especially in patients with genetic syndromes. Imaging (CT/MRI) surveillance may be necessary based on individual risk factors and genetic predisposition.

Treatment Algorithms

• First-Line:
  1. Biochemical Confirmation: Confirm diagnosis with plasma free metanephrines or 24-hour urine fractionated metanephrines/catecholamines.
  2. Imaging Localization: Localize the tumor(s) with CT or MRI. Functional imaging (MIBG, PET) for equivocal cases, extra-adrenal, or metastatic disease.
  3. Pre-operative Alpha-Blockade: Initiate alpha-blocker (e.g., phenoxybenzamine) for 7-14 days.
  4. Pre-operative Beta-Blockade and Volume Expansion: Add beta-blocker after alpha-blockade. Encourage high sodium/fluid intake.
  5. Surgical Resection: Laparoscopic adrenalectomy is the preferred approach for most benign adrenal pheochromocytomas. Open surgery may be required for very large tumors, extra-adrenal paragangliomas, or malignant disease. Complete tumor resection is the goal.
• Second-Line (for Malignant or Unresectable Disease):
  • Systemic Therapy:
    • Chemotherapy: The "CVD" regimen (cyclophosphamide, vincristine, dacarbazine) is a common option for metastatic pheochromocytoma/paraganglioma.
    • Targeted Therapy: Tyrosine kinase inhibitors (e.g., sunitinib) may be considered, especially for tumors with specific genetic mutations (e.g., VHL-associated).
  • Radionuclide Therapy:
    • $^{131}$I-MIBG Therapy: For patients with MIBG-avid metastatic disease, especially those with high tumor burden and progressive disease.
  • External Beam Radiation Therapy: For symptomatic bone metastases or local tumor control in unresectable sites.
  • Symptomatic Management: Optimize alpha- and beta-blockade to control symptoms from catecholamine excess.
• Refractory Cases:
  • Palliative Care: Focus on symptom control and improving quality of life.
  • Experimental Therapies/Clinical Trials: Consider enrollment in clinical trials for novel agents.
  • Debulking Surgery: For large, symptomatic tumors even if not curative.

Complications

• Common:
  • Hypertensive Crisis: Severe and abrupt elevation in blood pressure, potentially leading to end-organ damage.
  • Cardiac Arrhythmias: Tachycardia, atrial fibrillation, ventricular arrhythmias.
  • Diabetes Mellitus/Glucose Intolerance: Due to catecholamine-induced insulin resistance and impaired insulin secretion.
  • Anxiety/Panic Disorder: Often severe.
• Serious:
  • Cardiovascular: Myocardial infarction, congestive heart failure, acute pulmonary edema, dissecting aortic aneurysm, cerebrovascular accident (stroke), catecholamine-induced cardiomyopathy.
  • Renal: Acute renal failure.
  • Neurological: Seizures, intracranial hemorrhage.
  • Malignancy: Metastatic disease (most commonly to bone, lung, liver, lymph nodes).
  • Surgery-related: Intraoperative hypertensive crisis, severe hypotension post-resection (due to sudden withdrawal of catecholamines and persistent alpha-blockade), hemorrhage.
  • Sudden Death: From severe cardiac or cerebrovascular events.
• Long-term:
  • Residual Hypertension: Even after successful resection, some patients may have persistent hypertension requiring ongoing management.
  • Recurrence: Risk of tumor recurrence or development of new primary tumors, especially in genetic cases.
  • Cardiomyopathy: Chronic catecholamine excess can lead to irreversible cardiac damage.
  • Psychological Impact: Chronic anxiety, depression related to the diagnosis and surveillance.

Prognosis

• Factors Affecting Outcome:
  • Benign vs. Malignant: Most critical factor. Benign pheochromocytomas have an excellent prognosis after complete resection. Malignant pheochromocytomas have a significantly worse prognosis.
  • Completeness of Resection: Complete surgical removal is associated with better outcomes.
  • Genetic Syndrome: Certain mutations, particularly SDHB, are associated with an increased risk of malignancy and recurrence.
  • Location: Extra-adrenal paragangliomas (especially retroperitoneal) have a higher risk of malignancy than adrenal pheochromocytomas.
  • Tumor Size: Larger tumors are associated with a higher risk of malignancy.
  • Age at Diagnosis: Younger age can be associated with higher rates of genetic mutations and sometimes more aggressive disease.
• Survival:
  • Benign Pheochromocytoma: 5-year survival rate is >95% after successful surgical resection.
  • Malignant Pheochromocytoma/Paraganglioma: Prognosis is highly variable depending on the extent of metastasis and response to therapy. The 5-year survival rate typically ranges from 30% to 60%.
• Quality of Life: Generally good after successful resection of benign tumors, though some patients may experience persistent hypertension or anxiety. Long-term surveillance is necessary, which can impact psychological well-being. Patients with malignant disease often face significant challenges due to ongoing treatment and symptoms.

Prevention

• Primary Prevention: No known methods to prevent the initial occurrence of pheochromocytomas.
• Secondary Prevention (Early Detection):
  • Genetic Screening: Proactive genetic testing and counseling for individuals with a family history of pheochromocytoma/paraganglioma or related genetic syndromes (e.g., MEN2, VHL, NF1, SDH mutations).
  • Biochemical Surveillance: Regular biochemical screening (e.g., annual plasma or urine metanephrines) for individuals at high genetic risk (e.g., MEN2 patients, SDHB mutation carriers) to detect tumors early, often before symptoms develop or when they are small and curable.
  • Incidental Adrenal Mass Evaluation: Thorough biochemical workup of all incidental adrenal masses to rule out pheochromocytoma, even if asymptomatic.
• Tertiary Prevention (Preventing Complications):
  • Timely Diagnosis: Early and accurate diagnosis to initiate appropriate medical and surgical management.
  • Adequate Pre-operative Preparation: Meticulous alpha-adrenergic blockade and volume expansion to prevent intraoperative and postoperative complications.
  • Long-term Follow-up: Lifelong biochemical and imaging surveillance to detect recurrence or new primary tumors, especially in patients with genetic predispositions.

Special Populations

• Pediatric:
  • Higher Genetic Link: A higher proportion (up to 70%) are associated with germline mutations (especially MEN2, VHL, NF1, SDH).
  • Multifocal/Bilateral Disease: More common in children, particularly in genetic syndromes.
  • Diagnosis: Plasma free metanephrines are generally preferred due to ease of collection.
  • Management: Same principles as adults: alpha-blockade, followed by beta-blockade, then surgical resection. Radiation exposure from imaging needs careful consideration; MRI is often preferred.
• Geriatric:
  • Co-morbidities: Elderly patients often have multiple comorbidities (e.g., cardiovascular disease, renal impairment) that complicate management. Careful titration of alpha-blockers is crucial to avoid hypotension.
  • Atypical Presentation: Symptoms may be less pronounced or attributed to other age-related conditions.
  • Surgical Risk: Increased surgical risk due to age and comorbidities; multidisciplinary approach is essential.
• Pregnancy:
  • Diagnosis: Challenging as symptoms (headache, sweating, hypertension) can overlap with normal pregnancy or pre-eclampsia. Biochemical testing is safe. MRI is the preferred imaging modality to avoid fetal radiation exposure. MIBG is contraindicated due to radiation.
  • Management: Alpha-adrenergic blockade (e.g., phenoxybenzamine or selective alpha-1 blockers like prazosin, doxazosin) is the mainstay. Beta-blockers should be used with caution due to potential for fetal bradycardia or intrauterine growth restriction.
  • Timing of Surgery: If diagnosed in the first two trimesters, surgery (laparoscopic adrenalectomy) is ideally performed in the second trimester after adequate blockade. If diagnosed in the third trimester, medical management to term with planned C-section followed by tumor resection in the same sitting or postpartum is often preferred, to minimize fetal risk.
• Comorbidities:
  • Diabetes Mellitus: Pheochromocytoma can worsen glycemic control. Insulin or oral hypoglycemic agents may need adjustment. Resolution of catecholamine excess usually improves or resolves diabetes.
  • Cardiovascular Disease: Patients with pre-existing heart disease (e.g., coronary artery disease, cardiomyopathy) are at higher risk for cardiovascular complications during a hypertensive crisis or surgery. Intensive monitoring and careful medication titration are essential.
  • Renal Impairment: Affects elimination of some medications (e.g., metanephrines for urine tests) and antihypertensives; requires dose adjustments.

Clinical Pearls

• Diagnostic:
  • "Rule out pheo before you start beta-blockers in a hypertensive crisis." Unopposed alpha-adrenergic stimulation can lead to a severe, life-threatening hypertensive crisis.
  • Remember the classic triad: Palpitations, Headaches, Sweating. If a patient has these three symptoms, especially if paroxysmal and associated with hypertension, pheochromocytoma should be high on the differential.
  • Genetic testing is mandatory for all patients with a confirmed diagnosis of pheochromocytoma/paraganglioma.
  • An adrenal incidentaloma requires biochemical screening for pheochromocytoma, even if asymptomatic.
  • Plasma free metanephrines are generally the first-line diagnostic test due to high sensitivity and specificity. Ensure proper patient preparation (supine for 20-30 min, avoiding interfering substances).
• Treatment:
  • Alpha-blockade always precedes beta-blockade in pre-operative preparation.
  • Adequate intravascular volume expansion (high sodium diet and IV fluids) during alpha-blockade is crucial to prevent profound hypotension post-resection.
  • Laparoscopic adrenalectomy is the standard surgical approach for benign adrenal pheochromocytomas.
  • Lifelong biochemical surveillance is necessary post-operatively, especially in genetic cases, due to the risk of recurrence or new tumors.
• Pitfalls:
  • Misdiagnosing as anxiety or panic disorder: The symptoms can be very similar. Always consider pheochromocytoma in patients with resistant hypertension or paroxysmal symptoms, especially with a family history.
  • Starting beta-blockers before alpha-blockers: A critical error that can cause a severe hypertensive crisis.
  • Inadequate pre-operative preparation: Can lead to catastrophic intraoperative cardiovascular instability.
  • Missing extra-adrenal or metastatic disease: Not all pheochromocytomas are in the adrenal gland; imaging should be comprehensive, and functional imaging considered for high-risk cases.
  • Not performing genetic testing: Misses the opportunity to identify at-risk family members and guide long-term surveillance.

Recent Updates

• Guidelines: The Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma (2014) remains a key reference. The European Society of Endocrinology (ESE) also provides guidelines, with recent updates focusing on genetic testing and management of metastatic disease.
• Evidence:
  • Increased Recognition of Genetic Etiology: More than 50% of all pheochromocytomas/paragangliomas are now found to have a germline mutation, highlighting the importance of genetic testing for all patients.
  • Advanced Imaging: The role of $^{68}$Ga-DOTATATE PET/CT is expanding, proving highly sensitive for detection of primary tumors and metastases, especially in SDH-related paragangliomas, often outperforming MIBG scintigraphy.
  • Therapeutic Advances for Malignant Disease: Ongoing research into targeted therapies (e.g., tyrosine kinase inhibitors, mTOR inhibitors) and peptide receptor radionuclide therapy (PRRT) shows promise for patients with metastatic disease.
• Controversies:
  • Optimal Pre-operative Alpha-Blocker Regimen: While phenoxybenzamine is traditionally favored, the debate continues regarding the comparable efficacy and safety of selective alpha-1 blockers, particularly given phenoxybenzamine's long half-life and side effect profile.
  • Role of Genetic Testing in Normotensive Incidentalomas: The threshold for genetic testing in asymptomatic individuals with borderline biochemical results or small adrenal masses without classic features remains a point of discussion.
  • Management of Malignant Pheochromocytoma: No single curative treatment exists; the optimal sequence and combination of chemotherapy, radionuclide therapy, targeted agents, and external beam radiation continue to be debated and evolve.

Key References

• Guidelines:
  • Lenders, J. W., et al. (2014). Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 99(5), 1915-1942.
  • Lenders, J. W., et al. (2020). European Society of Endocrinology Clinical Practice Guideline for the management of patients with pheochromocytoma and paraganglioma. European Journal of Endocrinology, 182(4), 1-68.
• Studies:
  • Various landmark genetic studies identifying RET, VHL, NF1, SDH mutations as causes of hereditary pheochromocytoma/paraganglioma.
  • Studies evaluating the diagnostic accuracy of plasma free metanephrines and 24-hour urine fractionated metanephrines and catecholamines.
  • Clinical trials for management of malignant pheochromocytoma/paraganglioma, including radionuclide therapy and targeted agents.
• Reviews:
  • Recent comprehensive reviews published in journals such as The Lancet Diabetes & Endocrinology, New England Journal of Medicine, and Endocrine Reviews.

---

Disclaimer: This information is provided for educational purposes only and should not be considered medical advice. It is intended for healthcare professionals to serve as a comprehensive clinical reference. Clinical decisions regarding patient care must always be made by a qualified healthcare professional, considering individual patient circumstances, available evidence, and current clinical judgment. Dosage and treatment recommendations may need to be adjusted based on patient factors, co-morbidities, and local guidelines. Always consult official drug prescribing information and current clinical guidelines.